In adults with fatty liver disease who do not have diabetes, taking liraglutide for 12 weeks leads to better blood sugar control and lower liver fat production compared to weight loss from lifestyle...
Mechanism
Synthesis from 1 study
The drug helps the body use sugar more efficiently, which reduces fat production in the liver. When you stop taking it, fat tissue becomes inflamed and gut bacteria change in a way that makes the body store more fat and handle sugar worse, undoing all the benefits.
Most probable mechanism
When the drug is taken, it helps the pancreas release more insulin only when blood sugar is high, which lets muscles and fat tissue soak up more glucose. This lowers the amount of sugar available for the liver to turn into new fat, reducing liver fat buildup. When the drug is stopped, fat tissue starts releasing inflammatory signals and the gut bacteria shift toward a profile linked to weight gain, causing blood sugar control and liver fat production to return to their original levels.
GLP-1 receptor activation enhances glucose-dependent insulin secretion from pancreatic beta cells
Increased insulin signaling promotes glucose uptake into subcutaneous adipose tissue, reducing circulating glucose levels
Lower systemic glucose availability reduces substrate flux into the hepatic de novo lipogenesis pathway, decreasing new fatty acid synthesis in the liver
Cessation of GLP-1 receptor signaling disrupts transcriptional regulation in subcutaneous adipose tissue, increasing expression of pro-inflammatory genes
Dysregulated adipose tissue releases inflammatory proteins into circulation, promoting systemic metabolic instability
Loss of GLP-1 receptor signaling shifts gut microbiome composition toward a higher Firmicutes-to-Bacteroidetes ratio, associated with increased energy harvest and inflammation
Elevated systemic inflammation and altered microbial metabolism restore hepatic glucose flux and de novo lipogenesis, reversing improvements in glucose tolerance and liver fat synthesis
Evidence from Studies
Supporting (1)
Community contributions welcome
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.